GLP-1 Insurance Denial: How to Appeal and Win in 2026

Denials come in a handful of distinct flavors, and identifying which one you received determines everything you do next. Your denial letter — sometimes called an Explanation of Benefits or an adverse determination — will state a reason. Find it before you do anything else.

Plan exclusion. Your employer or plan simply doesn't cover weight-loss medications at all. This is the most common and most difficult category. As of the 2025 KFF Employer Health Benefits Survey, only about 19% of large employer plans covered GLP-1s for weight loss. Several major carriers tightened further for 2026, with Blue Cross Blue Shield excluding Wegovy, Saxenda, and Zepbound from pharmacy benefits at plan renewal for all indications except type 2 diabetes.

Prior authorization not met. The plan covers the drug in principle, but your submitted paperwork didn't satisfy their criteria — often a BMI threshold, a documented comorbidity, or proof of a supervised lifestyle attempt. Among people whose plans do cover GLP-1s for weight loss, 88% still face additional requirements like prior authorization.

Step therapy. The plan requires you to try and fail a cheaper option first — commonly phentermine, orlistat, or naltrexone-bupropion — before approving a GLP-1.

Non-preferred formulary status. The drug is covered, but not the one you were prescribed. CVS Caremark's 2025 decision to drop Zepbound in favor of Wegovy generated an enormous volume of these.

Missing documentation. A chart note wasn't attached, a diagnosis code was wrong, or a weight was recorded outside the required window. These are the easiest to fix and, frankly, a large share of first denials.

Our [complete guide to lowering GLP-1 costs](/blog/how-to-get-glp1-cheaper-savings-cards-telehealth-2026) covers the parallel routes if coverage genuinely isn't available.

Federal law gives you a structured, time-bound appeal process, and the deadlines matter more than most people realize because missing one can end your case regardless of its merit.

Internal appeal (level one). You have at least 180 days from the date of the denial notice to file. The insurer must respond within 30 days for a prescription not yet filled, or 60 days for a service already received. If your health is at urgent risk, you can request an expedited appeal, which requires a decision within 72 hours.

Internal appeal (level two). Many plans offer a second internal review, often with a different reviewer or a medical director in the relevant specialty. Not all plans have this step — the denial letter will say.

External review. If internal appeals fail, you can request review by an Independent Review Organization — a third party with no financial stake in the outcome. You generally have four months after the final internal denial to request it. The decision is binding on the insurer. This step is where a meaningful number of medically-necessary denials get overturned, because the reviewer is a physician evaluating clinical evidence rather than a plan applying its own criteria.

Self-funded employer plans work slightly differently — they fall under ERISA rather than state insurance law, so the external review pathway is federal. Medicare and Medicaid have their own separate appeal ladders with different timelines.

One strategic note: file the internal appeal even if you expect to lose it. External review usually requires that you exhaust internal appeals first. Skipping the step you think is futile can close the door on the step that actually works.

If you're on Medicare specifically, coverage rules changed meaningfully — see [Medicare and GLP-1 coverage in 2026](/blog/does-medicare-cover-glp1-weight-loss-drugs-2026).

Specificity. Appeals that win read like clinical documents; appeals that lose read like complaints.

The centerpiece is a letter of medical necessity from your prescriber. A strong one contains, in plain order:

• •Your current BMI, with the measured height and weight and the date taken
• •Every weight-related comorbidity you carry, with ICD-10 codes: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease, osteoarthritis, PCOS
• •A documented history of prior weight-management attempts — programs, dates, outcomes
• •Why alternatives are inappropriate or have failed, named specifically
• •Clinical evidence supporting the requested drug for your situation, cited by trial name
• •A direct statement that the treatment is medically necessary, and what happens clinically without it

Citing the trials by name genuinely helps, because it moves the letter from opinion toward evidence. SELECT (NEJM 2023) found semaglutide reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease and overweight or obesity, without diabetes. SURMOUNT-OSA supported tirzepatide for obstructive sleep apnea. STEP 9 addressed knee osteoarthritis. If any of those describe you, that's not a general argument for weight loss — it's a specific, FDA-recognized indication.

Also attach the plan's own criteria and walk through them point by point. If the policy requires a BMI of 30, or 27 with a comorbidity, show exactly where your chart meets it. Reviewers respond to a checklist they can tick.

What doesn't help: emotional appeals about quality of life on their own, general statements that obesity is a disease, or anger directed at the reviewer. All understandable. None persuasive to a utilization-management department.

This is the hardest denial to beat, because the plan isn't saying you don't qualify — it's saying the benefit doesn't exist. But there are still several real routes.

Look for a separate qualifying diagnosis. This is the most productive angle by a wide margin. Most 2026 exclusions carve out type 2 diabetes. Semaglutide also carries an FDA indication for cardiovascular risk reduction in people with established cardiovascular disease plus overweight or obesity, and tirzepatide is approved for moderate-to-severe obstructive sleep apnea with obesity. If you have any of these documented, the drug is no longer being requested as a weight-loss medication — it's being requested for a covered condition. That distinction wins cases.

Request a formulary exception. Plans must maintain a process for requesting non-covered drugs when covered alternatives are ineffective or harmful for you. This is a different process than an appeal, and prescribers sometimes don't realize it's available.

Check whether it's a formulary swap rather than a full exclusion. If your plan dropped Zepbound but covers Wegovy, switching medications may be far faster than appealing. Our comparison of [Wegovy versus Zepbound](/blog/wegovy-vs-zepbound-which-wins-for-weight-loss-2026) covers what that switch actually means for results.

Go through HR, not just the insurer. For self-funded employer plans, the employer — not the insurance company — decides what's covered. The carrier is just administering someone else's rules. Benefits managers do change formularies, especially when multiple employees raise it during open enrollment.

Document everything in writing. Phone calls vanish. Get reference numbers for every call, note the representative's name and the date, and follow up important conversations with an email summarizing what was said.

You still have meaningful options, and it's worth knowing them before you're exhausted from fighting.

Manufacturer savings and direct-purchase programs. Both Eli Lilly and Novo Nordisk run self-pay channels that price vials substantially below list. These bypass insurance entirely and don't require any authorization. Prices and eligibility shift, so check current terms directly. Our guide to [GLP-1 savings cards and cash prices](/blog/glp1-savings-cards-cash-prices-lower-cost-2026) breaks down how these compare.

Patient assistance programs. Income-based programs exist through both manufacturers for people who are uninsured or underinsured. The applications are long, but approval means the medication at little or no cost.

Telehealth platforms. Many now offer flat monthly pricing that includes the medication and clinical oversight. Quality varies enormously — see [how to evaluate GLP-1 telehealth providers](/blog/glp1-telehealth-providers-how-to-get-a-prescription-online-2026).

HSA and FSA dollars. A prescribed GLP-1 is an eligible expense, which effectively discounts the cost by your marginal tax rate. Details in our [FSA and HSA guide](/blog/glp1-fsa-hsa-pre-tax-dollars-save-on-weight-loss-2026).

Your state insurance commissioner. If you believe the plan violated its own terms or mishandled the process, a complaint to the state regulator is free and sometimes prompts a quick reconsideration.

Open enrollment. Coverage isn't permanent. If a spouse's plan covers GLP-1s, or a different plan option at your employer does, that's a once-a-year door.

And it's worth saying plainly: none of this is a referendum on whether you deserve treatment. Coverage decisions are budget decisions made at a population level. They are not clinical judgments about you.

It can, though not on its own — the argument works when menopause is framed as the driver of the comorbidities that plans already recognize.

The menopausal transition brings measurable metabolic shifts that are well documented in the SWAN study (Study of Women's Health Across the Nation): a redistribution of fat toward the abdomen, accelerating loss of lean mass, rising LDL cholesterol and triglycerides, and a steepening cardiovascular risk trajectory. These aren't vague complaints. They're chartable findings with diagnosis codes.

So the effective framing in an appeal is not 'she is menopausal and gaining weight.' It's: 'This patient has developed dyslipidemia (E78.5) and prediabetes (R73.03) during the menopausal transition, with visceral adiposity documented by a waist circumference of X cm, placing her at elevated cardiometabolic risk.' The second version names covered conditions.

There's also a legitimate evidence angle. A post hoc analysis of the SURMOUNT program published in *Obesity* (2025) found tirzepatide produced consistent weight reduction across reproductive stages — roughly 26% in premenopausal, 23% in perimenopausal, and 23% in postmenopausal women at the maximum tolerated dose. That matters for an appeal because it directly counters any suggestion that the medication is less effective in this population.

If you're also on hormone therapy, mention it. A retrospective cohort published in 2025 found postmenopausal women using menopausal hormone therapy alongside tirzepatide lost more weight than those on tirzepatide alone. We covered that research in [combining HRT and GLP-1](/blog/hrt-and-glp1-together-can-you-combine-them).

Bring the same specificity to the rest of your file — measured waist circumference, lipid panel, A1c, blood pressure readings, sleep study results if you have them. Numbers are what reviewers can act on.